Can we discontinue synthetic disease-Modifying anti-Rheumatic drugs in rheumatoid arthritis?

Clinical and Experimental Rheumatology

Volumn 31, Issue SUPPL.78, 2013, Pages

  Scott, Ian C ^a,b   Kingsley, Gabrielle H ^c,d   Scott, David L ^d  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY S HOSPITAL   (United Kingdom)

^c UNIVERSITY HOSPITAL LEWISHAM   (United Kingdom)

^d KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Agents anti rheumatic; Autoantibodies; Rheumatoid arthritis

Indexed keywords

AZATHIOPRINE; CHLOROQUINE; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GOLD; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PENICILLAMINE; PREDNISOLONE; RHEUMATOID FACTOR; SALAZOSULFAPYRIDINE;

ARTICLE; COMBINATION CHEMOTHERAPY; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG COMBINATION; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG RESPONSE; DRUG WITHDRAWAL; HUMAN; LOW DRUG DOSE; MONOTHERAPY; OBSERVATIONAL STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84885765791     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. GOEKOOP-RUITERMAN YPM, de VRIESBOUWSTRA JK, ALLAART CF et al.: Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005; 52: 3381-90.
2. RANTALAIHO V, KORPELA M, LAASONEN L et al.: Early combination disease-modifying antirheumatic drug therapy and tight disease control improve long-term radiologic outcome in patients with early rheumatoid arthritis: the 11-year results of the Finnish Rheumatoid Arthritis Combination Therapy trial. Arthritis Res Ther 2010; 12: R122.
3. DEIGHTON C, O'MAHONY R, TOSH J, TURNER C, RUDOLF M, Guideline Development Group: Management of rheumatoid arthritis: summary of NICE guidance. BMJ 2009; 338: b702.
4. SMOLEN JS, LANDEWé R, BREEDVELD FC et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69: 964-75.
5. AGARWAL S, ZAMAN T, HANDA R: Retention rates of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis. Singapore Med J 2009; 50: 686-92.
6. ALETAHA D, STAMM T, KAPRAL T et al.: Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in rheumatoid arthritis: a matched observational study. Ann Rheum Dis 2003; 62: 944-51.
7. MONTAG K, GINGOLD M, BOERS A, LITTLEJOHN G: Disease-modifying anti-rheumatic drug usage, prescribing patterns and disease activity in rheumatoid arthritis patients in community-based practice. Intern Med J 2011; 41: 450-5.
8. MAETZEL A, WONG A, STRAND V, TUGWELL P, WELLS G, BOMBARDIER C: Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving diseasemodifying anti-rheumatic drugs. Rheumatology (Oxford) 2000; 39: 975-81.
9. YAZICI Y, SOKKA T, KAUTIAINEN H, SWEARINGEN C, KULMAN I, PINCUS T: Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities. Ann Rheum Dis 2005; 64: 207-11.
10. MARADIT-KREMERS H, NICOLA PJ, CROWSON CS, O'FALLON WM, GABRIEL SE: Patient, disease, and therapy-related factors that influence discontinuation of diseasemodifying antirheumatic drugs: a population- based incidence cohort of patients with rheumatoid arthritis. J Rheumatol 2006; 33: 248-55.
11. AHERN MJ, HALL ND, CASE K, MADDISON PJ: D-penicillamine withdrawal in rheumatoid arthritis. Ann Rheum Dis 1984; 43: 213-7.
12. de SILVA M, HAZLEMAN BL: Long-term azathioprine in rheumatoid arthritis: a doubleblind study. Ann Rheum Dis 1981; 40: 560-3.
13. GOTZSCHE PC, HANSEN M, STOLTENBERG M et al.: Randomized, placebo controlled trial of withdrawal of slow-acting antirheumatic drugs and of observer bias in rheumatoid arthritis. Scand J Rheumatol 1996; 25: 194-9.
14. KREMER JM, RYNES RI, BARTHOLOMEW LE: Severe flare of rheumatoid arthritis after discontinuation of long-term methotrexate therapy. Double-blind study. Am J Med 1987; 82: 781-6.
15. ten WOLDE S, BREEDVELD FC, HERMANS J et al.: Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet 1996; 347: 347-52.
16. van der LEEDEN H, DIJKMANS BA, HERMANS J, CATS A: A double-blind study on the effect of discontinuation of gold therapy in patients with rheumatoid arthritis. Clin Rheumatol 1986; 5: 56-61.
17. O'MAHONY R, RICHARDS A, DEIGHTON C, SCOTT D: Withdrawal of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2010; 69: 1823-6.
18. PINCUS T, MARCUM SB, CALLAHAN LF: Long-term drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. J Rheumatol 1992; 19: 1885-94.
19. ten WOLDE S, HERMANS J, BREEDVELD FC, DIJKMANS BA: Effect of resumption of second line drugs in patients with rheumatoid arthritis that flared up after treatment discontinuation. Ann Rheum Dis 1997; 56: 235-9.
20. BOERS M, VERHOEVEN AC, MARKUSSE HM et al.: Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. [Erratum appears in Lancet 1998; 351: 220]. Lancet 1997; 350: 309-18.
21. LANDEWé RBM, BOERS M, VERHOEVEN AC et al.: COBRA combination therapy in patients with early rheumatoid arthritis: longterm structural benefits of a brief intervention. Arthritis Rheum 2002; 46: 347-56.
22. MOTTONEN T, HANNONEN P, LEIRISALOREPO M et al.: Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FINRACo trial group. Lancet 1999; 353: 1568-73.
23. MARCHESONI A, BATTAFARANO N, ARREGHINI M, PANNI B, GALLAZZI M, TOSI S: Radiographic progression in early rheumatoid arthritis: a 12-month randomized controlled study comparing the combination of cyclosporin and methotrexate with methotrexate alone. Rheumatology (Oxford) 2003; 42: 1545-9.
24. KLARENBEEK NB, van der KOOIJ SM, GULER-YUKSEL M et al.: Discontinuing treatment in patients with rheumatoid arthritis in sustained clinical remission: exploratory analyses from the BeSt study. Ann Rheum Dis 2011; 70: 315-9.
25. CLEGG DO, DIETZ F, DUFFY J et al.: Safety and efficacy of hydroxychloroquine as maintenance therapy for rheumatoid arthritis after combination therapy with methotrexate and hydroxychloroquine. J Rheumatol 1997; 24: 1896-902.
26. TISHLER M, CASPI D, YARON M: Methotrexate treatment of rheumatoid arthritis: is a fortnightly maintenance schedule enough? Ann Rheum Dis 1992; 51: 1330-1.
27. DOYLE DV, PERRETT D, FOSTER OJ, ENSOR M, SCOTT DL: The long-term use of D-penicillamine for treating rheumatoid arthritis: is continuous therapy necessary? Br J Rheumatol 1993; 32: 614-7.
28. FLEISCHMANN RM, COHEN SB, MORELAND LW et al.: Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial. Curr Med Res Opin 2005; 21: 1181-90.
29. GOEKOOP-RUITERMAN YPM, HUIZINGA TWJ: Rheumatoid arthritis: can we achieve true drug-free remission in patients with RA? Nat Rev Rheumatol 2010; 6: 68-70.
30. van der WOUDE D, YOUNG A, JAYAKUMAR K et al.: Prevalence of and predictive factors for sustained disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: results from two large early arthritis cohorts. Arthritis Rheum 2009; 60: 2262-71.
31. TIIPPANA-KINNUNEN T, PAIMELA L, KAUTIAINEN H, LAASONEN L, LEIRISALO-REPO M: Can disease-modifying anti-rheumatic drugs be discontinued in long-standing rheumatoid arthritis? A 15-year follow-up. Scand J Rheumatol 2010; 39: 12-8.
32. SINGH JA, FURST DE, BHARAT A et al.: 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res 2012; 64: 625-39.